» Articles » PMID: 38999077

Identification of 3-((4-Hydroxyphenyl)amino)propanoic Acid Derivatives As Anticancer Candidates with Promising Antioxidant Properties

Abstract

Various cancer-associated morbidities remain a growing global health challenge, resulting in a significant burden on healthcare systems worldwide due to high mortality rates and a frequent lack of novel therapeutic options for advanced and localized disease. Reactive oxygen species (ROS) play an important role in cancer pathogenesis and response to chemotherapeutics; therefore, it is crucial to develop novel compounds with both antioxidant and anticancer activity. In this study, a series of previously reported 3-((4-hydroxyphenyl)amino)propanoic acid derivatives (compounds -) were evaluated for their anticancer and antioxidant activities. Compounds , -, and were able to reduce A549 cell viability by 50% and suppress A549 cell migration in vitro. These compounds also showed favorable cytotoxicity properties towards noncancerous Vero cells. The most promising candidate, compound , exhibited potent antioxidant properties in the DPPH radical scavenging assay. These results demonstrate that 3-((4-hydroxyphenyl)amino)propanoic acid could be further explored as an attractive scaffold for the development of novel anticancer and antioxidant candidates.

References
1.
Lewandowska U, Gorlach S, Owczarek K, Hrabec E, Szewczyk K . Synergistic interactions between anticancer chemotherapeutics and phenolic compounds and anticancer synergy between polyphenols. Postepy Hig Med Dosw (Online). 2014; 68:528-40. DOI: 10.5604/17322693.1102278. View

2.
Kavaliauskas P, Grybaite B, Sapijanskaite-Banevic B, Vaickelioniene R, Petraitis V, Petraitiene R . Synthesis of 3-((4-Hydroxyphenyl)amino)propanoic Acid Derivatives as Promising Scaffolds for the Development of Antimicrobial Candidates Targeting Multidrug-Resistant Bacterial and Fungal Pathogens. Antibiotics (Basel). 2024; 13(2). PMC: 10886201. DOI: 10.3390/antibiotics13020193. View

3.
Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan X . Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials. 2021; 277:121110. DOI: 10.1016/j.biomaterials.2021.121110. View

4.
Srinivas U, Tan B, Vellayappan B, Jeyasekharan A . ROS and the DNA damage response in cancer. Redox Biol. 2019; 25:101084. PMC: 6859528. DOI: 10.1016/j.redox.2018.101084. View

5.
Boldrini J, Costa M . Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy. IMA J Math Appl Med Biol. 2000; 17(1):33-51. View